Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.

The American journal of drug and alcohol abuse - 4 Jul 2022

Butt Zahid A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Carbamates
Share to Cyclopropanes
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Lactams, Macrocyclic

Share to Opioid-Related Disorders

Share to Quinoxalines

Source

Identifiers

PMID: 35838498
DOI: 10.1080/00952990.2022.2091451

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.PMID 35838498Read ↗

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.Semantic proximity Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.Semantic proximity Read ↗

Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.Semantic proximity Read ↗

Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C.Semantic proximity Read ↗

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Semantic proximity Read ↗

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

Elbasvir/Grazoprevir with or without Sofosbuvir for Patients with Chronic Hepatitis C Virus Infection Post Solid Organ TransplantationSemantic proximity Read ↗

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.